<SEC-DOCUMENT>0001995601-25-000004.txt : 20250811
<SEC-HEADER>0001995601-25-000004.hdr.sgml : 20250811
<ACCEPTANCE-DATETIME>20250811130430
ACCESSION NUMBER:		0001995601-25-000004
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250811
DATE AS OF CHANGE:		20250811

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813676773
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-86953
		FILM NUMBER:		251201180

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Otto Erik
		CENTRAL INDEX KEY:			0001995601
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		641 OLIVER STREET
		CITY:			VICTORIA
		STATE:			A1
		ZIP:			V8S4W2
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001995601-24-000007</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001995601</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>American Depository Shares, each of which represent twenty ordinary shares, no par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>08/11/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001534248</issuerCik>
        <issuerName>Chemomab Therapeutics Ltd.</issuerName>
        <issuerCusip>36322Q107</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>KIRYAT ATIDIM, BUILDING 7</com:street1>
          <com:street2>KIRYAT ATIDIM, BUILDING 7</com:street2>
          <com:city>TEL AVIV</com:city>
          <com:stateOrCountry>L3</com:stateOrCountry>
          <com:zipCode>6158002</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Otto Erik</reportingPersonName>
      <citizenshipOrOrganization>A1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>1690000.00</soleVotingPower>
        <soleDispositivePower>1690000.00</soleDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1690000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>8.1</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>Percent of class based on 20,764,302 ADSs outstanding as of July 23, 2025 (As provided by the Issuer)</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Chemomab Therapeutics Ltd.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>KIRYAT ATIDIM, BUILDING 7, KIRYAT ATIDIM, BUILDING 7, TEL AVIV, ISRAEL, 6158002</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Erik Otto</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>144 West Oakview Place, San Antonio, Texas, 78209</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Canada</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>1,690,000</amountBeneficiallyOwned>
        <classPercent>8.1</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>1,690,000</solePowerOrDirectToVote>
          <solePowerOrDirectToDispose>1,690,000</solePowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Otto Erik</reportingPersonName>
      <signatureDetails>
        <signature>Erik Otto</signature>
        <title>Individual</title>
        <date>08/11/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
